NGDI-UBC Annual Report 2012R

Developing interventions for

neglected global diseases and

ensuring their delivery

to those in need.

Table of Contents

3

4

6

7

15

19

20

23

Advisory Board Members . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Director’s Report . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . NGDI Model of Collaboration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . NGDI Project Pipeline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Member Profiles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Funding Awards . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Events and Activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Membership List with Publications . . . . . . . . . . . . . . . . . . . . . . . . . .

Advisory Board Members

3|Advisory Board Members

Ms. Jennifer Choi Past-President, Student Biotechnology Network

Mr. Jonathan Edwin Co-Chair, Universities Allied for Essential Medicines

Ms. Kimberly Girling President, Student Biotechnology Network

Dr. Robert E.W. Hancock Professor, Department of Microbiology & Immunology, Faculty of Science; Director, Centre for Microbial Diseases and Immunity Research

Ms. Janis Horne Director of Development, Faculty of Pharmaceutical Sciences

Mr. Terry Kellam Director, Office of the Vice President Research and International

Dr. Charles Larson Professor, Department of Pediatrics, Faculty of Medicine; Director, Centre for International Child Health

Mr. Angus Livingstone Managing Director, University-Industry Liaison Office

Dr. Jennifer Love Professor, Department of Chemistry, Faculty of Science

Dr. Emily Marden Research Associate, Faculty of Law

Mr. Jonathan Mong Co-Chair, Universities Allied for Essential Medicines

Ms. Krista Sheppard Associate Director, Development, Faculty of Science

Dr. Jerry Spiegel Professor, School of Population and Public Health and Liu Institute for Global Issues

Dr. Sam White Project Development Scientist, Centre for Drug Research & Development

The NGDI-UBC Advisory Board is made up of a diverse group of UBC faculty, staff and students. The Board

meets monthly to guide the decisions of the NGDI and has played an integral part of the program’s growth.

We thank the Advisory Board members for their dedication and enthusiasm.

Neglected Global Diseases Initiative at UBC

Director’s Report |4

It’s my pleasure to report on the work of The Neglected Global Diseases Initiative in 2012. First I would

like to sincerely thank Managing Director, Angus Livingstone and the University-Industry Liaison Office for

housing and providing administrative support for our Coordinator, Jocelyn Conway from April 2010 until

November, 2012. This contribution has been much appreciated by Jocelyn and me as well as the NGDI

Advisory Board. The NGDI office has now moved into the new Pharmaceutical Sciences building and the

faculty is now contributing office space.

Our report this year provides some individual highlights, for instance Dr. Steve Morgan is a member of

the Consultative Expert Working Group on Research and Development: Financing and Coordination formed

by the World Health Organization to examine which potential methods could

alleviate the lack of progress in the drug pipeline for diseases of the poor.

The committee’s report was released last April and put before a wide WHO

audience in November. The results of that meeting and on-going meetings

this month (Jan, 2013) indicate the members of the WHO are not ready to

take any drastic actions towards fixing this problem anytime soon.

That is why news of new combinations of old drugs is a promising

method to move forward: for instance our member Dr. Santi Ramón-García

of the Centre for Tuberculosis Research at UBC has found that older iver-

mectins are showing success in-vitro not only against regular tuberculosis

but also multi-drug resistant TB. This could lead to real world treatment in a

much shorter time than developing a clinically unknown entity. Our report also highlights Dr. Charles Larson

for his long commitment and exemplary work in Bangladesh.

The NGDI-UBC has had some success this year in building bridges to the global health community across

Canada and the World Health Organization. We delivered our contracted literature review on the quality of

pediatric medicines in developing countries to the Essential Medicines and Health Products division of the

WHO and a version of this is in press right now. We hope that the findings of this report add to the momen-

tum of strengthening quality control measures and drug surveillance programs throughout lower-income and

lower-middle-income countries (LMICs). We would also like to thank Raquel Baldwinson, Atulya Bhardwaj,

Arianne Dee, and Katherine Hornby for their work on our new database project—more to come on this next

year.

There is also momentum across Canada to develop an international training program for global health

and the NGDI will be hosting a key stakeholders meeting for this in May, 2013. This program would involve all

the major global health groups in Canada and provide training for LMIC participants to train here and return

home with continuing support from their institution and Canadian trainees receiving global health training in

countries endemic with neglected diseases. The future of neglected disease work is in the hands of the stu-

dents and we recognize the importance of this developing idea.

A little closer to home, our Distinguished Lectureship Seminar Series continued in 2012 with diverse

speakers, starting with the Honourable Dr. Keith Martin, former Member of Parliament who is a staunch sup-

porter of global health work from a Canadian perspective. We also featured UBC ‘s Dr. Brett Finlay who edu-

Director’s Report

2012 Annual Report

cated the audience on his fascinating work in the world of microbiomes and how antibiotics have a powerful

effect to change this system and its response to diarrheal disease and asthma. There will much more fasci-

nating work coming out of this field. We ended the year with a visit from Dr. Clive Ondari of the WHO Essential

Medicines and Health Products branch who educated our students about the inner workings of the WHO and

helped expand the horizons of those who might be interested in global health work in the future. We will con-

tinue to offer talks that inspire our membership in working towards health equity in the world. We will be

starting off the new year with the President and Chief Executive Officer of Grand Challenges Canada, Dr. Peter

Singer.

It would be remiss not to mention a few outstanding researchers who received awards this past year.

Dr. Robert E.W. Hancock received the distinguished Prix Galien Research Award and both he and Dr. Brett Fin-

lay received Queen Elizabeth II Diamond Jubilee Medals. Dr. Jennifer Love received a Humbolt Research Fel-

lowship for her sabbatical year in Germany. The Hirsch-Index Benchmarking of Academic Research (HiBAR)

which measures both productivity and impact of a researcher’s work named Dr. Hancock and Dr. Steve With-

ers as Stars in Research.

Funding for our members this year indicates that we have a very active group of people that in total re-

ceived over $23 million dollars. We worked hard to develop multidisciplinary teams for grant proposals and

held workshops to develop ideas. We also held an NGDI stakeholder meeting to bring ideas to the table about

future directions for the initiative. Not only do we continue to receive the support of the upper administration

but our membership is involved, interested and continues to forge ahead.

Our report this year highlights our Model of Collaboration (to be explained more fully on the next page),

project pipeline, membership funding, our events and activities, and for the first time offers a full list of our

membership along with their 2012 relevant publications. The year ahead looks bright and I would personally

like to thank the membership and the Advisory

Board for their support and encouragement over

the last year.

Dr. Kishor M. Wasan

Professor and Associate Dean of Research and

Graduate Studies and Distinguished University

Scholar

Faculty of Pharmaceutical Sciences

5|Director’s Report

Of the patients waiting at the Out-Patient Department of Apac Hospital in Northern Uganda, the majority are mothers of children under 5 years old with malaria.


The NGDI has, since its inception, prioritized multidisciplinary collaboration in our core mandate. The

model that we use to guide our membership and to categorize our projects is an extension of the traditional

drug discovery pipeline with Frost & Reich’s Access Framework1. The access framework suggests that without

an architecture that supports availability, affordability and adoption, there is little chance of successfully deliv-

ering interventions to those in need.

This new model provides a research roadmap that also recognizes the necessity of fundamental feed-

back between the discovery and development of interventions, and the delivery and policy work needed on

affordability and adoption. They must inform each other to be successful. A new medicines can take from 14-

20 years of time to reach the market and when it does, there is no guarantee that means it will get to the right

people. Time could be saved for implementation when recognition is given at an early stage to the end-user

and their particular culture and viewpoints. Delivery research into supply chain dynamics, health systems and

strengthening (recently defined as operational, implementation and systems research2) is as crucial as afforda-

bility (patents, IP agreements) and end-user adoption research.

On the following eight pages we list our researchers’ ongoing projects under the main headings of

our model of collaboration. Both our membership and the types of projects we highlight are diverse. Our

definition of neglected global diseases includes neglected tropical diseases as well as the big 3 (HIV/AIDS,

malaria and tuberculosis) but also many conditions that affect the bottom billion of the worlds people. We

are bringing investigators together who have a strong interest in working with others on larger projects and

developing teams that can make a real difference.

NGDI Model of Collaboration |6

2012 Annual Report

NGDI Model of Collaboration

1. Frost LJ, Reich MR 2008. Access: How do good health technologies get to poor people in poor countries? Cambridge: Harvard University Press.

2. Remme JHF, Adam T, Becerra-Posada F, D’Arcangues C, Devlin M, et al. (2010) Defining Research to Improve Health Systems. PLoS Med 7(11): e1001000.

doi:10.1371/journal.pmed.1001000.

Model of Collaboration

Health Systems Research – Health financing, governance and policy. Prob-lems pertaining to structuring, manage-ment, planning, human resources, ser-vice delivery, and quality of care.

Implementation Research – Multidisci-plinary research for new or available health interventions to improve access and the use by population in need.

Operational Research – To develop solutions to current operational prob-lems of specific health program or spe-cific service delivery component of the health system.

Synthesis of K777

Jennifer Love Department of Chemistry Chagas disease is the leading cause of heart failure in Latin America. Existing treatments for this disease have low efficacy and unacceptable side effects. Cruzain, the major cysteine protease of the causative organism Trypanosoma cruzi, is an optimal biological target for Chagas disease. K777 has shown exceptional activity against cruzain, but its existing synthesis is inefficient and is not readily amenable to analogue synthesis. We have developed a reaction that should provide a more convenient, cheaper route to K777 and analogues.

Meningococcal infection in HIV/AIDS

James Kronstad Department of Microbiology & Immunology The impact of Cryptococcal fungal pathogens in the HIV/AIDS population now rivals tuberculosis in Sub-Saharan Africa. There are an estimated one million cases of cryptococcal meningitis globally per year in AIDS patients, leading to approximately 625,000 deaths (Park et al., 2009. AIDS. 23: 525-530). Addition-ly Cryptococcus gattii has emerged as a pathogen of immunocompetent people. Our research focuses on the identification and characterization of candidate drug targets through the molecular genetic and genomic dissection of virulence mechanisms.

Ferrocenyl-carbohydrate Conjugates

Christopher Orvig Department of Chemistry Ferrocenoyl carbohydrate conjugates have potential as metalloantimalarials. The ferrocene moiety has proven to be a successful addition to known malaria therapeu-tics, increasing efficacy towards chloroquine resistant strains of the parasite. Combining the ferrocene moiety with a glucose derivative is a novel approach for developing targeted therapy. As well, glucose uptake and metabolism in infected erythrocytes is elevated at all stages of the parasite’s life cycle and glucose consumption has been a target in anti-malarial research.

Iron Uptake Systems

Michael Murphy Department of Microbiology and Immunology Staphylococcus aureus is a significant opportunistic Gram positive pathogen with a high prevalence of multiple drug resistance such as MRSA. Though gener-ally seen as a problem of the developed world, a recent article found “… that its neglected status as a developing world pathogen does not equate with low rates of disease.” The project is investigating iron uptake systems in Staphylococcus aureus.

Cysteine Protease Inhibitors

Jennifer Love Department of Chemistry Cysteine protease inhibitors have significant potential for use as therapeutics for parasitic diseases. Vinyl sulfones have been demonstrated to be an effective class of cysteine protease inhibitors with exceptional selectivity for protozoan cysteine proteases. We have developed methodology that greatly improves access to a wide range of vinyl sulfones. We anticipate that this methodology will be broadly applicable for the synthesis of potential drugs for the treatment of malaria, Chagas disease, leishmaniasis and African sleeping sickness.

Drug Discovery

Antibiotic Resistance

Chagas HIV/AIDS

Malaria

7|NGDI-UBC 2012 Annual Report

NGDI Project Pipeline

Synthesis of Antimalarial Agents

Gregory Dake Department of Chemistry We are currently working to develop new sets of chemical entities to treat malaria that will have activity against resistant strains. We will achieve this through chemical modification that simplifies the core struc-ture of the naturally occurring compound simaomicin a, an extremely potent antimalarial agent. Current projects involve the synthesis of simaomicin a itself, as well as the generation of simplified analog structures.

Pertussis (Bordetella pertussis)

Rachel Fernandez Department of Microbiology & Immunology B. pertussis is the Gram negative bacterium that caus-es whooping cough. Despite being a “vaccine-success story”, pertussis accounts for 81,000 deaths annually worldwide. Although most cases of pertussis can be prevented by vaccination, this does not generate life-long immunity, which underscores the need for alternative vaccine strategies or inexpensive booster vaccines. I am interested in the molecular mechanisms of microbial pathogenesis, particularly the mecha-nisms that allow colonization and carriage of Bordetel-la pertussis.

CD4+T Helper 2 Cytokines

Colby Zaph Department of Pathology & Laboratory Medicine Trichuris is a soil-transmitted nematode parasite that infects humans and animals. Resistance to re-infection is acquired with age and is associated with the expression of CD4+ T helper 2 (TH2) cytokines. Anti-helminthic treatment is effective but provides only a short-term benefit, thus, problems of repeated infections, coupled with increasing cases of drug resistance and growing costs of developing new chemotherapeutic agents, dictate an increasing requirement for long-term immunological intervention strategies.

Tuberculosis

Pertussis

Soil-transmitted Helminthes

Centre for Tuberculosis Research at UBC

The CTBR at UBC is dedicated to the development of novel therapeutics to curb the effects of the most devastating infectious agent of mortality worldwide, Mycobacterium tuberculosis (Mtb).

Vision: To promote cutting-edge collaborative oppor-tunities in the disciplines of microbiology, biochemistry, immunology and chemistry to better understand bio-logical systems that can be used as targets for new drugs for tuberculosis chemotherapy.

Mission: To understand the scientific basis of Mtb’s prevalence, including its inherent resistance to antibi-otics and its unusual ability to persist in the host and to develop and optimize novel anti-bacterials that target Mtb.

Selected current projects: The identification of new potential drug combinations to overcome the intrinsic resistance of M. tuberculosis; the identification of M. tuberculosis enzymes that degrade cholesterol – a ma-jor nutrient source during infection and the characteri-zation of M. tuberculosis signalling proteins that disrupt host function.

Project Pipeline |8

A nurse in a local clinic in Huambo Province, Angola, checks a patient

and her baby before prescribing anti-malarial drugs.

Oral Formulation of Amphotericin B

Kishor Wasan Faculty of Pharmaceutical Sciences In developed countries, fungal infections are a leading contributor to death among immunocompromised indi-viduals (e.g. cancer and AIDS patients). In the develop-ing world, leishmaniasis is contracted by 2 million peo-ple a year. Dr. Wasan’s formulation, being developed to be taken orally without serious side-effects, will be a significant improvement on the current treatment which is expensive, can only be administered by injec-tion and is highly toxic. This makes the technology ideal for application in the developing world, and our com-mercialization agreement with iCo ensures that devel-opment of the formulation will embrace our global ac-cess objectives.

Since partnering with iCo Therapeutics Inc., preclinical data show that significant antifungal activity was seen at dosage levels where no kidney toxicity was ob-served, and the tropically stable formulation displayed a dramatic knock-down of a parasitic infection that causes Visceral Leishmaniasis (VL), with greater than 99% eradication of parasitic infection at the tested dosages. Recent data also suggest that AmpB may be able to activate latent HIV infection, which would allow current HAART therapy to be more effective.

Innate Defense Regulators

Robert Hancock Department of Microbiology & Immunology Supported by the Grand Challenges in Global Health program, innate defense regulator (IDR) peptides were developed that work by selectively modulating innate immunity (enhancing protective innate immunity while suppressing potentially harmful pro-inflammatory re-sponses). IDRs have demonstrated, both alone and in the presence of suboptimal antimicrobial treatments (mimicking situations of resistance), protection in ani-mal models against invasive S. aureus infections, local

Drug Development Leishmaniasis

Vaccines

thigh S. aureus infections, MRSA, VRE, and Salmonella, as well as protection in mice against E. coli, P. aerugino-sa, M. tuberculosis, Franciscella, Citrobacter, Pox virus, and cerebral malaria, many with collaborators. These effects can be relatively modest ranging from a 1-4 log change in bacterial load to 75% increase in survival, but are accompanied by a decreased inflammatory re-sponse and substantially reduced morbidity.

Vaccine Adjuvants

Robert Hancock Department of Microbiology & Immunology IDR peptides show efficacy as components of vaccine adjuvants. In collaboration with the Vaccine Infectious Diseases Organization in Saskatoon, we created a for-mulation of three adjuvant components that gives (protective) antibody titres (mixed Th1/Th2 response) of 40,000 in a single injection against a model antigen pertussis toxoid; furthermore we have evidence that this works via the mucosal route and in adult and neo-natal mice and pigs. Protection exceeds that afforded by the commercial vaccine Quadracel.


Development of Fixed Drug Dosing Bands

Charles Larson Department of Pediatrics The purpose of this project is to simplify assessment and treatment decision making, as well as communica-tion between health providers, thru the development of weight or proxy for weight bands. In Phase I the validity of drug dosing decisions based upon weight bands and proxies were tested and validated using existing data sets from Uganda and Bangladesh. In Phase II these bands will be color coded and tested for accuracy, validity and feasibility under more-or-less ideal conditions (efficacy) within both countries. In Phase III a similar exercise will be carried out, but under actual conditions (effectiveness) in rural health centres. Weight band proxies to be tested include age, height, and long bone measurements (tibia and ulna).

Low-Cost Malaria Diagnostic

Hongshen Ma Department of Mechanical Engineering Accurate, sensitive, and cost-effective diagnostic tests are central to the global campaign to control and erad-icate malaria. Inaccurate diagnosis not only results in patient mortality and morbidity, but also leads to in-effective use of treatment resources and could accel-erate the emergence of drug-resistant strains.

Malaria is caused by a protozoan parasite that invades human red blood cells. We are developing a low-cost and portable device for detection of malaria infection that can quantitatively determine parasite density and discriminate viable and non-viable parasites. Micro-scopic examination of blood smears are not as amenable to low-resource settings and rap-id diagnostic tests to not speci-fy viable vs non-viable para-sites. Our device could be used to direct treatment until the clearance of all viable par-asites, as well as to evaluate the effectiveness of new drugs and vaccines in clinical trials.

Project Pipeline |10

Meeting capacity-building and scaling-up challenges to sustainably prevent and control dengue in Machala, Ecuador

Jerry Spiegel School of Population & Public Health Dengue is a neglected mosquito-borne viral disease, for which there is no vaccine. This project aims to evaluate the effectiveness, cost and acceptability of an Eco-Bio-Social approach to controlling and preventing Dengue in Ecuador, in comparison to traditional insecticide-based control programs. The Eco-Bio-Social approach includes a school-based anti-dengue education campaign, a safe water storage and clean patio com-munity campaign and anti-dengue community work-shops. Collaboration is with the Universidad Andina de Simon Bolivar, BCCDC and the Universidad Tecnica de Machala and funding is provided by WHO TDR Special Programme for Research on Diseases of Poverty.

Innate DataBase

Robert Hancock Department of Microbiology & Immunology To enhance systems biology studies in the areas of host pathogen interactions and innate immunity, we devel-oped InnateDB (www.innatebd.com), an open-source, publicly available database and systems biology anal-ysis platform of the genes, proteins, interactions and signalling responses involved in the human & mouse innate immune responses.

InnateDB is becoming an important tool in immunology as evidenced by the >1,500,000 hits per year. While all known human and mouse pathways (>3,000) and molecular interactions (>115,000) are present, the emphasis on innate immunity has been achieved through our contextual review, curation and annota-tion of >12,000 molecular interactions and pathways involved in innate immunity.

We have demonstrated the usefulness of this tool in systems analyses of host responses to a variety of important pathogens including human clinical datasets: typhoid and malaria in Vietnam, non typhoidal Salmo-nella infections in AIDS patients in Malawi, helminth infections in children in Ecuador, and mouse models of Cerebral Malaria and M. tuberculosis.

Vector Control, Tools & Diagnostics Dengue Fever

Tool Malaria

Diagnostics


Reducing malaria related child mortality in Uganda: Defining a sustainable community self-management program

Rosemin Kassam School of Population and Public Health In Uganda, it is estimated that more than 39,000 children less than five years of age die annually from malaria. Evidence suggests that over 50% of house-holds purchase their drugs from unregulated drug vendors, which are often of questionable quality and/or incorrect dose and quantity. In partnership with Ugandan researchers, a community-based self-management intervention is being proposed to improve the practice of unregulated drug vendors and increase health literacy among caregivers.

Review of the Quality of Pediatric Medicines in Developing Countries

Jocelyn Conway, Kishor Wasan Neglected Global Diseases Initiative The World Health Organization’s (WHO) Model List of Essential Medicines for Children (EMLC) was published in its latest version on March, 2011. The list is intended to guide therapeutic treatment for priority conditions for children up to twelve years of age. There are 207 core and 70 supplementary medicines. While there have been reviews of disease specific medicines such as antimicrobials and antimalarials, there has been no known review of the quality of all medicines on the EMLC. In addition, little data exists on the quality of pediatric formulations, such as suspensions and syrups. It is also presently unknown to what extent there may be adverse clinical effects associated with the use of substandard or counterfeit medicines for children under the age of twelve. This project will review the literature for the quality of pediatric medicines in developing countries. Funding is provided by the WHO.

Supply Chain

Global mHealth (WelTel)

Richard Lester Faculty of Medicine Clinical research interests include using mobile information technology (cell phones) to improve patient support and health services in resource-limited settings. This initial work in Kenya was featured on CBC’s The National, highlighted by the World Health Organization Essential Medicines Monitor, and published in Nature. This work represents the first com-parative outcomes research showing effectiveness of mHealth for HIV and health outcomes in a developing world setting (published in The Lancet online Nov. 9th, 2010). We are working to scale up the project and ex-panding to include health conditions other than HIV.

Operational Research

Malaria

Medications

HIV/AIDS

Nine month old receives her measles vaccination in Ethiopia's Merawi province.


Implementation Research

Scale Up of Zinc Treatment of Childhood Diarrhea

Charles Larson Department of Pediatrics This project aims to support the effective and sustained scale-up of the treatment of childhood diarrhea with zinc and ‘low osmolarity Oral Rehydration Salts (ORS), so as to contribute in turn to the reduction of diarrhea-related child morbidity and mortality in Senegal. This support will be used to improve both the health-seeking behaviour of caregivers during diarrhea epi-sodes of children and the accessibility, utilization, and coverage of high quality diarrhea treatment with zinc and low osmolarity ORS.

Interrupting Pathways to Childhood Sepsis

Charles Larson Department of Pediatrics Early detection and interruption of pathways to sepsis among women, newborns and young children in least developed countries has been a largely neglected and misunderstood issue. Sepsis is the final common path-way to death for nearly all serious childhood infectious illnesses. Of the nearly 7 million under-five children who die each year, it is estimated that 50 to 70% of these deaths will be the result of children entering this pathway. In partnership with several Bangladeshi and Canadian organizations, this project will establish demonstration sites in which integrated innovations will be implemented and evaluated that involve the coordinated actions of communities, midwives, and primary or hospital care providers in adopting and strengthening mHealth communication and diagnostic innovations, early intervention [detection + referral/transport + treatment] of childhood infections and strengthened health systems.

Diarrheal Disease

Sepsis

HIV/AIDS and Tuberculosis

Eclampsia and Pre-eclampsia

Prevention, Diagnosis, and Treatment of HIV and TB in the Workplace

Annalee Yassi School of Population and Public Health With funds from the Global Health Research Initiative’s Canadian HIV Vaccine Initiative program, we are devel-oping, implementing, and evaluating a program to build capacity in South Africa to implement and evaluate programs for prevention, diagnosis, and treatment of HIV and TB in the workplace. This project uses our online learning modules, as well as problem-based learning, but especially community-based learning, as all participants have to implement and evaluate HIV and TB in their own workplaces as part of their training.

Prediction in Pre-Eclampsia

Peter von Dadelszen Department of Obstetrics & Gynecology PIERS (Pre-eclampsia Integrated Estimate of RiSk) We are investigating a range of potential predictors of ad-verse maternal outcomes in women admitted to hospi-tal with pre-eclampsia. We identified the feasibility of, and need to perform, a prospective outcome prediction model development and initial validation study, which was completed in seven centres internationally with CIHR support. This model, the PIERS model, is now be-ing re-validated in two versions.

The first version, fullPIERS, is for use in well-resourced settings and is being validated in level I-III units in Cana-da, New Zealand, Australia, and the UK in women with pre-eclampsia and the other hypertensive disorders of pregnancy. The validation of fullPIERS has the support of the CIHR.

In parallel, we are also validating the miniPIERS model, which is symptom and signed-based, for use in rural and remote communities and low and middle income countries. The re-validation of miniPIERS has the sup-port of the World Health Organization and the CIHR, and is taking place in Brazil, Pakistan, Mali, China, Uganda, South Africa, and Fiji.

Children shown with bednets distriubuted through a Malaria

Community project in Angola.

Implementation of Occupational Health and Safety Information System (OHASIS)

Annalee Yassi, Jerry Spiegel School of Population and Public Health With funds from the Canadian Institutes for Health Research, we are implementing and evaluating a web-based information system (being piloted in Free State, South Africa, as well as the South African National Health Laboratory Service) to help track workplace incidents, exposures, workplace hazards, personal risk factors, vaccines, training, treatment and the full spectrum of health outcome of health workers. Led by Dr. Jerry Spiegel, this project to study the implementa-tion of the Occupational Health and Safety Information System (OHASIS) is subtitled “Tool, Weapon or White Elephant” in our effort to understand whether this health information system is actually beneficial.

The Intellectual Property and Policy Research Group (IPPRG)

This group is a collaboration of interdisciplinary re-searchers from law, sociology, philosophy and science backgrounds who are interested in the convergence of technology, innovation and translation. Our research has been funded by members’ participation in a number of Genome Canada projects. Our research is centred on alternative and conventional intellectual property regimes (IPRs) such as:

Genomics and Technology Transfer/Development Offices

Patent Pools and Essential Medicines

Open Source Drug Discovery and Development

Research Tool Patents & the Experimental Use Exemption

Public Domain as an Alternative IPR

IP and Regulatory Policy for Neglected Disease Drug Development

IP and Plant Genomics

Health Systems Research

We outline the technical basis for each model and identify the ethical and practical issues at stake, includ-ing the promotion of public health, the location of proprietary rights and detailed examinations of the distribution of cost and benefits.

The Impact of International Agreements on Health

Benjamin Warren Liu Institute for Global Issues The North American Free Trade Agreement (“NAFTA”) was the first international trade agreement to include harmonization provisions to protect IP and remains an important source of obligations for the three NAFTA state parties. The Trade Related Aspects of Intellectual Property (“TRIPS”) agreement is the global multilateral legal instrument governing substantive IP law. I am currently using comparative legal analysis and qualita-tive methods for illuminating how member countries of NAFTA are meeting their harmonization obligations and adapting their IP systems through available flexibilities to promote pharmaceutical R&D and Access.

Health Systems Strengthening

Intellectual Property

Policy Work on Affordability & Adoption


Women wait by their sick babies while they receive treatment, in the munici-

pal hospital of M'banza Congo, Zaíre province.

Neglected Disease Pharmaceutical R&D Busi-ness Models: An Assessment of Alternatives

Benjamin Warren Liu Institute for Global Issues The traditional business model for pharmaceutical development has been of start-up companies licensing patented academic research leading to a product that allows R&D costs to be recovered through sales at qua-si-monopolistic prices. While this market model works to some extent, it is not optimal as it rations access to new medicines through elevated prices and does not create incentives to develop treatments for small mar-kets. My research question examines whether “It is possible to construct business models that improve incentives for both access and innovation?” I analyze traditional and new models that have been proposed, including prize funds, patent pools, product develop-ment partnerships (PDPs), and advance purchase commitments (APCs).

A Historical View of Pharmaceutical Innovation

Steve Morgan School of Population and Public Health Using a variety of government and academic data sources, we are studying trends in innovation in the pharmaceutical market over the past 80 years. Our hypothesis is that discrete waves of category-defining innovation occurred at key points in the pharmaceuti-cal industry’s history and that the industry is currently between periods of significant therapeutic discovery – – caught between the drugs-by-design revolution that began in the late 1970s and still-emerging biopharma-ceutical revolution of the early 21st century. We are using information on the timing, number and nature of new drugs to come to market and on drug sales and generic market penetration to test hypotheses and illuminate market dynamics.

Research & Development Incentives for Valued Innovation in the Pharmaceutical Sector Steve Morgan School of Population and Public Health This is a study of the economics of pharmaceutical innovation. We include a systematic review of estimates of cost of drug development, a conceptual framework for defining pharmaceutical innovation, and a detailed review of incentives for innovation. We illustrate the implications of patents as a tool for providing private sector incentives, highlighting how patents provide “forward looking” incentives by rewarding the product of research and development and how they are “plutocratic” in the sense that incentives are proportional to the wealth of the end market. We review policy interventions required to provide incentives for investment in desired health innovations in developed and developing countries.


Pediatric polio vaccination, India.

Dr. Charles Larson

Director, Centre for International Child Health Dr. Charles Larson has been committed to working with disadvantaged populations since his

medical school days. At that time he was a co-founder of the first community-directed health cen-

tre in Canada, located in the low-income community of Pointe St. Charles in Montreal. It is this early experi-

ence that ultimately steered Charles towards global health. He has now been engaged in global health for

nearly 25 years of his academic career. This includes having worked in Ethiopia and Bangladesh – each for 6

years. He moved to Vancouver in 2008 to become the Director, Centre for International Child Health at BC

Children’s Hospital and a clinical professor in the Department of Pediatrics. He is also the co-Lead of the Global

and Indigenous Health Theme within the School of Population and Public health. He has been a member of

the Advisory Board of the NGDI-UBC since 2009.

As a clinical research pediatrician as well as a specialist in preventive medicine and public health, child

survival and the scaling up of proven life-saving interventions have been his main focus. He has had a decade

long involvement with the world renowned International Centre for Diarrheal Disease Research, Bangladesh

(ICDDR,B), at first leading the first national campaign to scale up zinc treat-

ment of childhood diarrhea. He states, “Today, approximately 40% of chil-

dren with diarrhea in Bangladesh receive zinc treatment – saving thousands

of lives, while in most developing countries less that 1% receive zinc.”

More recently he has initiated a project addressing the prevention or

early detection and treatment of sepsis in mothers, newborns and under-

five children. This latter project is in partnership with the Bangladesh Minis-

try of Health and Family Welfare, ICDDR,B and faculty from UBC and McGill.

It is funded by CIDA through its Muskoka Initiative Partnership Program.

Dr. Larson believes that early detection and interruption of pathways to sepsis in least developed

countries has been a largely neglected and misunderstood issue. He comments, “Sepsis is the final common

pathway to death for nearly all serious childhood infectious illnesses. Of the nearly 7 million under-five

children who die each year, it is estimated that 50 to 70% of these deaths will be the result of children entering

the sepsis pathway.”

His project will establish demonstration sites where integrated innovations will be implemented and

evaluated that involve the coordinated actions of communities, midwives, primary care providers, mHealth

communication and diagnostic support, aggressive early treatment with antimicrobials and fluids, strength-

ened referral and transport systems, and zinc supplementation of syndromic sepsis survivors. In true NGDI

fashion this will involve health professionals, but also engineers, designers, social scientists and health

administrators.

Developing a long-term partnership with international institutions, such as ICDDR,B, and committing to

sustained partnerships within a country are crucial to strengthening health systems and attaining improve-

ments in health outcomes. We commend Dr. Larson for his work in Bangladesh and his commitment to

furthering the cause of health equity.

15|Member Profile

“Sepsis is the final

common pathway to

death for nearly all

serious childhood

infectious illnesses.”

Member Profile


“Of the nearly 7 million under-five children who die each year, it is

estimated that 50 to 70% of these deaths will be the result of children

entering the sepsis pathway.”

Dr. Charles Larson |16

A 22 year old mother 4 days post-partum arriving at a local hospital with fever and abdominal pain for 3 days.

2012 Annual Report

17| Member Profile

“Major changes are possible and governments can be convinced to

make commitments needed to implement reforms consistent with the

CEWG recommendations.”


Dr. Steve Morgan

Associate Director, Centre for Health Services and Policy Research Dr. Steve Morgan’s interest in pharmaceutical policy was solidified when as an under-

grad a teacher recommended he read–“Strained Mercy” a classic health economics textbook. There he

learned that his interests in the economics of innovation, social policy, industrial organization, and equity

came together in one area. Over time he has become an expert in the analysis of causes and consequences of

prescription drug utilization and spending, as well as the political and economic factors that influence the

availability and accessibility of medical technologies.

His previous work with Health Canada earned him a nomination and selection for a place in the Con-

sultative Expert Working Group on Research and Development (CEWG) of the World Health Organization. The

main work of this body was to examine proposals for new and innovative sources of financing to stimulate re-

search and development (R&D) utilizing the principal of de-linking the cost of R&D with the price of medicines

for the improvement of access to essential medicines in all countries, but

especially in low income countries that need them most. Dr. Morgan states,

“De-linking is a difficult but not impossible task in the political economy that

is the pharmaceutical sector. Firms frequently cite dramatic estimates of the

cost of drug development as rationale for high prices. But governments are

increasingly realizing that no purchaser of medicines anywhere in the world

should consider R&D costs when deciding what to pay for a medicine.”

The CEWG’s report, released in April 2012, supported the de-linking

strategy with a proposal for a binding convention to coordinate a global R&D

fund and recommendations for a UN Observatory for R&D along with other

advisory bodies. These are bold objectives and perhaps not surprisingly, in November, when the report came

before the member states of the WHO only one recommendation was passed; that of an observatory body.

The rest of the report was tabled until 2016. This response has drawn some criticism from those member

states and NGO’s who realize the dire need for change, however, Dr. Morgan is not discouraged, commenting,

“Major changes are possible and governments can be convinced to make commitments needed to implement

reforms consistent with the CEWG recommendations. Prices can be appropriately de-linked only when govern-

ments provide ‘de-linked incentives’ for innovation and put appropriate policies in place for production and

distribution. That’s possible by 2020 but will take political leadership at the highest level.”

Dr. Morgan’s latest work at the CHSPR has involved evaluating the barriers to evidence-based decision

making for health policy makers and understanding the history of the changing scientific and policy paradigms

in the pharmaceutical sector. He advices students interested in the economics of health innovation to get a

solid foundation in micro- and welfare economics as well as studying population health.

The NGDI congratulates Dr. Morgan impact on Canadian pharmaceuticals policy as well as his work on

the CEWG and looks forward to following this story and supporting the CEWG’s recommendations.

Dr. Steve Morgan |18

“De-linking is a

difficult but not

impossible task in

the...pharmaceutical

sector.”

Member Profile

2012 Annual Report

January Dr. David Grierson, received funding from the Canadian Institutes of Health Research (CIHR) in the amount of $399,168. The project is Development of specific inhibitors of alternative splicing events crucial to HIV replication: A new anti-HIV/AIDS strategy.

February Dr. Richard Lester received a Grand Challenges Canada award through the Stars in Global Health in the Canada Direct Entry phase. This $100,000 grant will further his ground-breaking work on SMS texting in HIV/AIDS treatment titled WelTel: Moving Evidence to Action for Patient-Centred mHealth.

April Lyndsay O’Hara received doctoral funding for 3 years from the CIHR for $105,000. Her research is “Reducing nosocomial transmission of tuberculosis in South Africa: A population-based molecular epidemiologic study.”

May Dr. Richard Lester and Co-investigator Dr. Fawziah Marra received $350,000 from CIHR for “Improving health system efficiency in latent tuberculosis treat-ment through text messaging.”

June iCo Therapeutics and Drs. Kishor and Ellen Wasan

The NGDI-UBC gratefully acknowledges the partnership and contributions

of the following organizations.

19|Funding Awards

Funding Awards

received $1.1 million from the National Research Council of Canada for “The development of Oral Amphotericin B for HIV treatment.”

Dr. Richard Lester received a $545,361 award from the US National Institutes of Health for “WelTel retain: Promoting engagement in pre-ART HIV care through SMS.“

Dr. Tobias Kollmann received $600,000 from the CIHR for a new team network called “Maternal-infant microbiome and immunity network (MIMI).”

Dr. Timothy Green received funding from the Interna-tional Development Research Centre and the Canadian International Development Agency of $2.9 million for his focus on “Improving nutrition of rural Cambodian women and children.”

November Dr. Hongshen Ma received a Grand Challenges Canada through the Stars in Global Health in the Canada Direct Entry phase. This $100,000 grant will further his work in developing a low-cost diagnostic screening tool— a “Low-cost and portable Hematology analyzer.”

December

Dr. Peter von Dadelszen received an additional $17 million from the Bill and Melinda Gates Foundation for the work on his “Pre-eclampsia, eclampsia project. “


January 14 & 21 Dr. Wasan gave talks about NGDI at the Student Leadership Conference and Faculty in Resident program.

January 2 An article co-written by Jimi Galvão, Jocelyn Conway, and Suzana Topic was published in the International Pharmacy Journal. Publication title: Looking outward, looking forward: Fighting neglected diseases with pharmaceutical sciences.

February 21 A joint press release from the CDRD and NGDI-UBC reported outcomes from the partnership formed one year ago.

February 24 Our fifth Distinguished Lectureship featured Dr. Keith Martin. His talk was titled: Bridging the knowledge action-gap: Politics, partnerships and new tools to address the global health challenges of our time.

January February

March 2 Celebrate Research Week event: Developing Drugs for Developing Countries. This event was co-sponsored with the Student Biotechnology Network and featured speakers from iCo Thera-peutics, Pharmaceutical Sciences, Entrepreneur-ship UBC, and the firm of Gowling, Lafleur, Hender-son.

March

Timeline of Activities and Events |20

Timeline of Activities and Events

2012 Annual Report

March 16-17 The NGDI-UBC was a ma-jor sponsor (in-kind) of the BC Forum of the Canadian Coalition for Global Health Research conference held in Wosk Centre for Dia-logue, Vancouver.

March 17 & 24 Dr. Wasan gave talks about NGDI at Amnesty International Conference at UBC and at Destination South Asia.

April 20 Our sixth Distinguished Lectureships featured Dr. Brett Finlay, Professor, Michael Smith Laboratories, Microbiology and Immunology at UBC. His talk was titled: The role of microbiata in enteric (diarrheal) and allergic (asthma) diseases.

May 4 An updated version of the Case Studies in Global Health was published. This project highlighted Dr. Kishor Wasan’s Oral AmB project originally in 2008.

June 25 The NGDI marks an outstanding month for funding for NGDI researchers totally over $4 million. Dr. Richard Lester, Dr. Tobias Kollmann, Dr. Timothy Green, and Drs. Kishor and Ellen Wasan and iCo Ther-apeutics received funding.

July 11 Dr. Kishor Wasan is inter-viewed for CBC Radio’s “The Invisible Hand” and featured in an episode titled: Profit and Capital-ism.

July 23 Jocelyn Conway delivered the Quality of Pediatric Medicines in Developing Countries contracted literature review to the WHO, Essential Medicines Branch. The report will be published in an upcoming WHO Bulletin.

August 27 An NGDI Stakeholder meeting was conducted on campus to facilitate member feedback on the development of new funding strategies and programming for the initiative.

August 29 Jocelyn Conway gave a talk to incoming Faculty of Pharmaceutical Graduate Research Students intro-ducing the NGDI and it’s mandate.

August 31 NGDI announced the fund-ing of three travelships to the AAPS annual meeting in Chicago. These $750 awards were given to students from the Univer-sity of Utah, University of Pittsburgh, and Indiana University.

August 19 Dr. Kishor Wasan spoke at the American Chemistry Society’s National meeting held in Philadelphia, USA.

March

July June

May April

August

21|Timeline of Activities and Events


September 10 A UBC news release re-ported that “Funding for neglected global disease research at UBC exceeded $20 million”. This release followed a September 3 mention in the Vancouver Sun in an article titled “University research pays back in terms of jobs and results”.

September 17 Kishor Wasan invited to give a briefing at the Asso-ciate Dean’s of Research meeting and introduce the NGDI to other faculties.

September 18 The Faculty of Pharmaceu-tical Sciences officially opened it’s new $133 million state-of-the-art building that not only doubles the student body for pharmaceutical sciences but also houses the NGDI partner Centre for Drug Research and Development.

September 26 NGDI co-sponsored a Pharmaceutical Science Graduate talk with Dr. Karl Werbovetz from Ohio State University. Dr. Wer-bovetz has worked with Dr. Wasan and is currently investigating new an-tileishmaniasis drug candi-dates.

October 14 News release from iCo Therapeutics reporting that the NGDI’s lead project Oral AmB is the subject of a 5 poster presentation at the AAPS annual meeting and also announced a new patent had been received in Singapore.

October Dr. Wasan was appointed to the Canadian Coalition for Global Health Research Board of Directors.

November 2 Our seventh Distinguished Lectureship featured Dr. Clive Ondari, Essential Medicines and Health Prod-ucts, World Health Organization. His talk was titled, “Providing evidence based norms, standards and guidelines for the delivery of health solutions”. Dr. Ondari was kept very busy after the talk with the line of students that wanted to chat with him.

November 5 The NGDI office moved to the fifth floor of the new pharmaceutical sciences building on Wesbrook Mall. The Faculty of Pharmaceutical Sciences will be providing in-kind office space and ongoing administrative support.

November 22 A UBC news release announced a new Centre for TB Research discovery of a new drug combination that targets both tubercu-losis and multi-drug resistant tuberculosis.

September October

November

Timeline of Activities and Events |22

2012 Annual Report

Membership List with Publications

This membership list contains all relevant (neglected diseases and conditions) publications from 2012 of our

diverse group of researchers, associate researchers, post-doctoral fellow and graduate students.

Mark Ansermino

Associate Professor, Department of Anesthesia Director, Innovations in Acute Care & Technology Research Cluster, CFRI Director of Research for Pediatric Anesthesia, BC Children’s Hospital

von Dadelszen P, Ansermino JM, Dumont G, Hofmeyr GJ, Magee LA, Mathai M, Sawchuck D, Teela K, Donnay F and Roberts JM. Improving maternal and perinatal outcomes in the hypertensive disorders of pregnan-cy: A vision of a community-focused approach. Int J Gynecol Obstet 2012 119(Suppl 1):S30-S34. DOI:10.1016/j.ijgo.2012.03.012.

Wiens MO, Kumbakumba E, Kissoon N, Ansermino JM, Ndamira A and Larson CP. Pediatric sepsis in the developing world: Challenges in defining sepsis and issues in post-discharge mortality. Clin Epidemiol 2012 4(1):319-325. DOI:10.2147/CLEP.S35693.

Horatio Bach

Clinical Assistant Professor Department of Infectious Diseases

Martinez Ruiz MG, Richard-Greenblatt M, Juarez ZN, Av-Gay Y, Bach H and Hernandez LR. Antimicrobial, anti-inflammatory, antiparasitic, and cytotoxic activi-ties of Laennecia confusa. Scientific World J 2012

2012:263572. DOI:10.1100/2012/263572.

Richard-Greenblatt M, Bach H and Av-Gay Y. A closer look at the biosyn-thetic pathway of ergothioneine in Mycobacterium tuberculosis. FEBS J

2012 279:192. DOI:10.1111/j.1742-4658.2010.08705.x.

Karen Bartlett

Associate Professor School of Environmental Health

Ibrahim F, Gershkovich P, Sivak O, Wasan EK, Bart-lett K, Wasan KM. Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis. Int J

Pharm 2012 436(1-2):318-323. DOI:10.1016/j.ijpharm.2012.06.062.

Ian Bell

Transfer Technology Manager University-Industry Liaison Office

Mary-Anne Bobinski

Dean Faculty of Law

William Bowie

Professor Department of Infectious Diseases

Marra F, Patrick DM, Chong M, McKay R, Hoang L and Bowie WR. Population-based study of the in-creased incidence of skin and soft tissue infections and associated antimicrobial use. Antimicrob Agents Chemother 2012 56(12):6243-6249. DOI:10.1128/AAC.00649-12.

Gary Brayer

Professor Department of Biochemistry and Molecular Biology

Gregory Dake

Associate Professor Department of Chemistry

Matthew Farrer

Professor Department of Medical Genetics

Rachel Fernandez

Associate Professor Department of Microbiology & Immunolo-

gy

Fernandez RC. Airborne transmission of bordetella pertussis demonstrated in a baboon model of whoop-ing cough. J Infect Dis 2012 206(6):808-810. DOI:10.1093/infdis/jis444.

Brett Finlay

Professor Department of Microbiology & Biochemistry

Achtman AH, Pilat S, Law CW, Lynn DJ, Janot L, Mayer M, Ma S, Kindrachuk J, Finlay BB, Brinkman FSL, Smyth GK, Hancock REW and Schofield L. Effective adjunctive therapy by an innate defense regulatory peptide in a pre-clinical model of severe malaria. Science Transl Med 2012 4(135):135ra64. DOI:10.1126/scitranslmed.3003515.

Antunes LCM, Wang M, Andersen SK, Ferreira RBR, Kappelhoff R, Han J, Borchers CH and Finlay BB. Repression of salmonella enterica phop ex-pression by small molecules from physiological bile. J Bacteriol 2012 194(9):2286-2296. DOI:10.1128/JB.00104-12.

Auweter SD, Yu HB, Arena ET, Guttman JA and Finlay BB. Oxysterol-binding protein (osbp) enhances replication of intracellular salmonella and binds the salmonella spi-2 effector ssel via its n-terminus. Microbes Infect

A

D

23|Membership List with Publications

B

F


http://dx.doi.org/10.1100%2F2012%2F263572

2012 14(2):148-154. DOI:10.1016/j.micinf.2011.09.003.

Backhed F, Fraser CM, Ringel Y, Sanders ME, Sartor RB, Sherman PM, Versalovic J, Young V and Finlay BB. Defining a healthy human gut microbi-ome: Current concepts, future directions, and clinical applications. Cell Host

and Microbe 2012 12(5):611-622. DOI:10.1016/j.chom.2012.10.012.

Cortes-Vieyra R, Bravo-Patino A, Valdez-Alarcon JJ, Juarez MC, Finlay BB and Baizabal-Aguirre VM. Role of glycogen synthase kinase-3 beta in the inflammatory response caused by bacterial pathogens. J Inflamm 2012 9:23 DOI:10.1186/1476-9255-9-23.

Ferreira RBR and Finlay BB. Identifying an immune signature against inva-sive Salmonella. Proc Natl Acad Sci USA 2012 109(13):4721-4722. DOI:10.1073/pnas.1201825109.

Gill N, Ferreira RBR, Antunes LCM, Willing BP, Sekirov I, Al-Zahrani F, Hart-mann M and Finlay BB Neutrophil Elastase Alters the Murine Gut Microbiota Resulting in Enhanced Salmonella Colonization. PLoS ONE 2012 7(11) DOI:10.1371/journal.pone.0049646.

Karch H, Denamur E, Dobrindt U, Finlay BB, Hengge R, Johannes L, Ron EZ, Tonjum T, Sansonetti PJ and Vicente M. The enemy within us: Lessons from the 2011 European Escherichia coli O104:H4 outbreak. EMBO Mol Med 2012 4(9):841-848. DOI:10.1002/emmm.201201662.

McCormick B and Finlay B. Special edition of Gut Microbes. Gut Microbes 2012 3(2):61. DOI:10.4161/gmic.19936.

Prehna G, Li Y, Stoynov N, Okon M, Vuckovic M, McIntosh LP, Foster LJ, Finlay BB and Strynadka NCJ. The zinc regulated antivirulence pathway of Salmonella is a multiprotein immunoglobulin adhesion system. J Biol Chem 2012 287(39):32324-32337. DOI:10.1074/jbc.M112.357210.

Sal-Man N, Biemans-Oldehinkel E, Sharon D, Croxen MA, Scholz R, Foster LJ and Finlay BB. EscA is a crucial component of the type III secretion sys-tem of enteropathogenic Escherichia coli. J Bacteriol 2012194(11):2819-2828. DOI:10.1128/JB.00103-12.

Shames SR and Finlay BB. Bacterial effector interplay: A new way to view effector function. Trends Microbiol 2012 20(5):214-219. DOI:10.1016/j.tim.2012.02.007.

Van Der Heijden J and Finlay BB. Type III effector-mediated processes in Salmonella infection. Future Microbiol 2012, 7(6):685-703.

DOI:10.2217/fmb.12.49.

John Forbes

Clinical Professor Department of Pediatrics

Timothy Green

Associate Professor Department of Food Nutrition and Health

David Grierson

Professor Faculty of Pharmaceutical Sciences

Otang WM, Grierson DS and Ndip RN. Phytochemical studies and antioxidant activity of two South African medicinal plants traditionally used for the management of opportunistic fungal infections in HIV/AIDS patients. BMC Complement Altern Med 2012 12:43. DOI:10.1186/1472-6882-12-43.

Urs Hafeli

Professor Faculty of Pharmaceutical Sciences

Robert EW Hancock

Professor

Department of Microbiology & Immunology

Director Centre for Microbial Diseases and Immunity Research Afacan NJ, Fjell CD and Hancock REW. A systems biology approach to nutritional immunology-focus on innate immunity. Molec Aspects Medi-

cine 2012 33:14-25. DOI:10.1016/j.mam.2011.10.013.

Afacan NJ, Yeung ATY, Pena OM and Hancock REW. Therapeutic potential of host defense peptides in antibiotic-resistant infections. Curr Pharm Design

2012 18(6):807-819. DOI:10.2174/138161212799277617.

Bains M, Fernández L and Hancock REW. Phosphate starvation promotes swarming motility and cytotoxicity in Pseudomonas aeruginosa. Appl Environ

Microbiol 2012 78(18):6762-6768. DOI:10.1128/AEM.01015-12.

Breidenstein EBM, Bains M and Hancock REW. Involvement of the Lon pro-tease in the SOS response triggered by ciprofloxacin in Pseudomonas aeru-ginosa PAO1. Antimicrob Agents Chemother 2012 56(6):2879-2887. DOI:10.1128/AAC.06014-11.

Brown THT, David J, Acosta-Ramirez E, Moore1 JM, Lee S, Zhong G, Hancock REW, Xing Z, Halperin SA and Wang J. Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vac-cines against genital Chlamydia muridarum infection. Vaccine 2012 30(2):350-360. DOI:10.1016/j.vaccine.2011.10.086.

de la Fuente-Núñez C, Korolik V, Bains M, Nguyen U, Breidenstein EBM, Horsman S, Lewenza S, Burrows L and Hancock REW. Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide. Antimicrob Agents Chemother 2012 56(5):2696-2704. DOI:10.1128/AAC.00064-12.

Fernández L, Breidenstein EBM, Song D and Hancock REW. Role of intracel-lular proteases in the antibiotic resistance, motility, and biofilm formation of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2012 56(2):1128-1132. DOI:10.1128/AAC.05336-11.

Fernández L and Hancock REW. Adaptive and mutational resistance: Role of porins and efflux pumps in drug resistance. Clin Microbiol Rev 2012 25(4):661-681. DOI:10.1128/CMR.00043-12.

Fjell CD, Hiss JA, Hancock REW, and Schneider G. Designing antimicrobial peptides: Form follows function. Nat Rev Drug Discov 2012 11:37-51. DOI:10.1038/nrd3591.

Fuente-Núñez C, Mertens J, Smit J and Hancock REW. The bacterial surface layer provides protection against antimicrobial peptides. Appl Environ Microbi-ol 2012 78(15):5452-5456. DOI:10.1128/AEM.01493-12. Covered in Nature Reviews Microbiology 10:442 DOI:10.1038/nrmicro2828.

Gao G, Cheng JTJ, Kindrachuk J, Hancock REW, Straus SK and Ki-zhakkedathu JN. Biomembrane interactions reveal the mechanism of action of surface-immobilized host defense IDR-1010 peptide. Chem Biol 2012 19(2):199–209. DOI:10.1016/j.chembiol.201.12.015.

Garlapati S, Garg R, Brownlie R, Latimer L, Simko E, Hancock REW, Babiuk L, Gerdts V, Potter A and van den Hurk S. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formu-lated with CpG oligodeoxynucleotide and synthetic innate defense regulator peptide in polyphosphazene microparticles. Vaccine 2012 30(35):5206-14. DOI:10.1016/j.vaccine.2012.06.011.

Gellatly SL, Needham B, Madera L, Trent MS and Hancock REW. The Pseu-domonas aeruginosa phoP-phoQ two-component regulatory system is in-

Membership List with Publications|24

G

H

2012 Annual Report

duced upon interaction with epithelial cells and controls cytotoxicity and in-flammation. Infect Immun 2012 80(9):3122-3131. DOI:10.1128/IAI.00382-12.

Hancock REW, Nijnik A and Philpott DJ. Modulating immunity as a therapy for bacterial infections. Nature Rev Microbiol 2012 10(4):243-254. DOI:10.1038/nrmicro2745.

Kazemzadeh-Narbat M, Noordin S, Masri BA, Garbuz DS, Duncan CP, Hancock REW and Wang R. Drug release and bone growth studies of antimi-crobial peptide-loaded calcium phosphate coating on titanium. J Biomed

Mater Res B-Appl Biomater 2012 100(5):1344-52. DOI:10.1002/jbm.b.32701.

Lin L, Tan B, Pantapalangkoor P, Ho T, Baquir B, Tomaras A, Montgomery JI, Reilly U, Barbacci EG, Hujer K, Bonomo RA, Fernandez L, Hancock REW, Adams MD, French SW, Buslon VS and Spellberg B. LpxC inhibition protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. mBio 2012 3(5) pii:e00312-12 epub. DOI:10.1128/mBio.00312-12.

Ma M, Kazemzadeh-Narbat M, Hui Y, Lu S, Ding C, Chen DDY, Hancock REW and Wang R. Local delivery of antimicrobial peptides using self-organized TiO2nanotube arrays for peri-implant infections. J Biomed Materials

Res Part A 2012 100A(2):278-285. DOI:10.1002/jbm.a.33251.

Madera L and Hancock REW. Synthetic immunomodulatory peptide IDR-1002 enhances monocyte migration and adhesion on fibronectin. J Innate

Immun 2012 4(5-6):553-568. DOI:10.1159/000338648.

Nijnik A, Clare S, Hale C, Chen J, Raisen C, Mottram L, Lucas M, Estabel J, Ryder E, Adissu H, Sanger Mouse Genetics Project, Adams NC, Ramirez-Solis R, White JK, Steel KP, Dougan G and Hancock REW. The role of sphin-gosine-1-phosphate transporter Spns2 in immune system function. J Immunol 2012 189:102-111. DOI: 10.4049/jimmunol.1200282. Featured in the “In This Issue” section of The Journal of Immunology.

Nijnik A, Pistolic J, Cho P, Filewod NCJ, Falsafi R, Ramin A, Harder KW and Hancock REW. The role of the Src family kinase Lyn in the immunomodulato-ry activities of cathelicidin peptide LL-37 on monocytic cells. J Leuk Biol 2012 91(4):599-607. DOI:10.1189/jlb.0411191.

Orchard S, Kerrien S, Abbani S, Aranda B, Bhate J, Bidwell S, Bridge A, Briganti L, Brinkman F, Cesareni G, Chatr-aryamontri A, Chautard E, Chen C, Dumousseau M, Eisenberg D, Goll J, Hancock REW, Hannick L, Jurisica I, Khadake J, Lynn DJ, Mahadevan U, Perfetto L, Raghunath A, Ricard-Blum S,

Roechert B, Salwinski L, Stümpflen V, Tyers M, Uetz P, Xenarios I and Hermjakob H. Protein Interaction Data Curation - The International Molecular Exchange Consortium (IMEx). Nature Methods 2012 9(4):345-350. DOI:10.1038/nmeth.1931.

Steinstraesser L, Hirsch T, Schulte M, Kueckelhaus M, Jacobsen F, Mersch EA, Stricker I, Afacan N, Jenssen H, Hancock REW and Kindrachuk J. Innate defense regulator peptide 1018 in wound healing and wound infection. PLoS

ONE 2012 7(8):e39373 epub. DOI:10.1371/journal.pone.0039373.

Wang G, Elliott M, Cogen AL, Ezell EL, Gallo RL and Hancock REW. Struc-ture, dynamics, antimicrobial and immune modulatory activities of human LL-23 and its single residue variants mutated on the basis of homologous pri-mate cathelicidins. Biochemistry 2012 51(2):653-664. DOI:10.1021/bi2016266.

Bonnie Henry

Assistant Professor School of Population and Public Health

Wilf Jeffries

Professor Department of Microbiology and Immunology and Medical Genetics

Rosemin Kassam

Associate Professor School of Population and Public Health

Svetlana Kishchenko

Clinical Assistant Professor School of Population and Public Health

Niranjan (Tex) Kissoon

Associate Head and Professor Department of Pediatrics Vice-President, Medical Affairs BC Children’s Hospital

Riley C, Basu RK, Kissoon N and Wheeler DS. Pediatric SepSis: Preparing for the future against a global scourge. Curr Infect Dis Rep 2012 14(5):503-511. DOI:10.1007/s11908-012-0281-5.

Reinhart K, Kissoon NT, Daniels R, Marshall J, Dellinger P and Jimenez EJ. What we learned from the first World Sepsis Day. J Crit Care 2012 27(6):735-736. DOI:10.1016/j.jcrc.2012.09.017.

Wiens MO, Kumbakumba E, Kissoon N, Ansermino JM, Ndamira A and Larson CP. Pediatric sepsis in the developing world: Challenges in defining sepsis and issues in post-discharge mortality. Clin Epidemiol 2012 4(1):319-

325. DOI:10.2147/CLEP.S35693.

Kochanek PM and Kissoon N. Pediatric Critical Care Medicine reaches an-other milestone. Pediatr Crit Care Med 2012 13(6):623-624. DOI:10.1097/PCC.0b013e31826b773d.

Reinhart K, Kissoon NT, Daniels R, Jimenez EJ. Stop sepsis-save lives: A call to join the global coalition for the World Sepsis Day. J Crit Care 2012 27(4):410-413. DOI:10.1016/j.jcrc.2012.06.010.

Dunser MW, Festic E, Dondorp A, Kissoon N, Ganbat T, Kwizera A, Haniffa R, Baker T and Schultz MJ. Point of care ultrasound for sepsis management in resource-limited settings: Response to Via et al. Intensive Care Med 2012 38(8):1408-1409. DOI:10.1007/s00134-012-2607-z.

Dunser MW, Festic E, Dondorp A, Kissoon N, Ganbat T, Kwizera A, Haniffa R, Baker T and Schultz MJ. Erratum: Recommendations for sepsis manage-ment in resource-limited settings (Intensive Care Medicine DOI: 10.1007/s00134-012-2468-5). Intensive Care Med 2012 38(4):575-576. DOI:10.1007/s00134-012-2521-4.

Dunser MW, Festic E, Dondorp A, Kissoon N, Ganbat T, Kwizera A, Haniffa R, Baker T and Schultz MJ. Recommendations for sepsis management in resource-limited settings. Intensive Care Med 2012 38(4):557-574.

DOI:10.1007/s00134-012-2468-5.


Frank Ko

Professor Department of Materials Engineering Director, Advanced Materials & Process Engineering Laboratory


J

K


Tobias Kollmann

Assistant Professor Department of Pediatrics

Al-Dabbagh M, Driessche KV, Marais BJ and Kollmann TR. Management of multi-drug-resistant tuberculosis in children. Eur Infect Dis 2012 6(1):35-40.

Dauby N, Goetghebuer T, Kollmann TR, Levy J and Marchant A. Uninfected but not unaffected: Chronic maternal infections dur-ing pregnancy, fetal immunity, and susceptibility to postnatal infections. Lancet Infect Dis 2012 12(4):330-340.

Kollmann TR, Levy O, Montgomery RR and Goriely S. Innate Immune Func-tion by Toll-like Receptors: Distinct Responses in Newborns and the Elderly. Immunity 2012 37(5):771-783. DOI:10.1016/j.immuni.2012.10.014.

Reikie BA, Adams RCM, Ruck CE, Ho K, Leligdowicz A, Pillay S, Naidoo S, Fortuno III ES, de Beer C, Preiser W, Cotton MF, Speert DP, Esser M and Kollmann TR. Ontogeny of Toll-Like Receptor Mediated Cytokine Responses of South African Infants throughout the First Year of Life. PLoS ONE 2012 7(9) DOI:10.1371/journal.pone.0044763.

Shey MS, Hughes EJ, De Kock M, Barnard C, Stone L, Kollmann TR, Hanekom WA and Scriba TJ. Optimization of a whole blood intracellular cytokine assay for measuring innate cell responses to mycobacteria. J Im-

munol Methods 2012 376(1-2):79-88. DOI:10.1016/j.jim.2011.11.011.

Slogrove A, Reikie B, Naidoo S, De Beer C, Ho K, Cotton M, Bettinger J, Speert D, Esser M and Kollmann T. HIV-exposed uninfected infants are at increased risk for severe infections in the first year of life. J Trop Pediatr

2012 58(6):505-508. DOI:10.1093/tropej/fms019.

James Kronstad

Professor Department of Microbiology & Immunology Director Michael Smith Laboratories

Charles Larson

Clinical Professor Department of Pediatrics Director Centre for International Child Health

Larson CP, Zinc supplementation for probable serious bacterial infection in early infancy may reduce the need for antibiotic change. Evid Based Med 2012 Published online Oct 20, 2012. DOI:10.1136/eb-2012-100925.

Larson CP, Koehlmoos TP, Sack DA; Scaling Up of Zinc for Young Chil-dren (SUZY) Project Team. Scaling up zinc treatment of childhood diar-rhoea in Bangladesh: theoretical and practical considerations guiding the SUZY Project. Health Policy Plan 2012 27(2):102-14. DOI:10.1093/heapol/czr015.

McElroy TA, Atim S, Larson CP, Armstrong RW. Risks to early childhood health and development in the postconflict transition of northern Uganda. Int J

Pediatr 2012. DOI:10.1155/2012/820290.


Richard Lester

Assistant Clinical Professor Department of Infectious Diseases

Mbuagbaw L, Thabane L, Ongolo-Zogo P, Lester RT,

Mills EJ, Smieja M, Dolovich L and Kouanfack C. The Cameroon Mobile Phone SMS (CAMPS) Trial: A Randomized Trial of Text Messaging versus Usual Care for Adherence to Antiretroviral Therapy. PLoS ONE 2012 7(12) DOI:10.1371/journal.pone.0046909.

Mills EJ, Lester R and Ford N. Adherence to antiretroviral therapy: Supervi-sion or support? Lancet Infect Dis 2012 12(2):97-98.

Mills EJ, Lester R and Ford N. Promoting long term adherence to antiretrovi-ral treatment. BMJ 2012, 344:e4173. DOI:10.1136/bmj.e4173.

Thirumurthy H and Lester RT. M-health for health behaviour change in re-source-limited settings: Applications to HIV care and beyond. Bull WHO 2012 90(5):390-392. DOI:10.2471/BLT.11.099317.

van der Kop ML, Karanja S, Thabane L, Marra C, Chung MH, Gelmon L, Kimani J and Lester RT. In-Depth Analysis of Patient-Clinician Cell Phone Communication during the WelTel Kenya1 Antiretroviral Adherence Trial. PLoS ONE 2012 7(9) DOI:10.1371/journal.pone.0046033.

Edward Levy

Adjunct Professor W. Maurice Young Centre for Applied Ethics

Angus Livingstone

Managing Director University-Industry Liaison Office

Angela Lo

Clinical Instructor, Faculty of Pharmaceutical Sciences Department of Pharmacy, Vancouver Coastal Health Au-thority

Jennifer Love

Associate Professor Department of Chemistry

Lawrence McIntosh

Professor Departments of Chemistry and Biochemistry & Molecular Biology

Prehna G, Li Y, Stoynov N, Okon M, Vuckovic M, McIn-tosh LP, Foster LJ, Finlay BB and Strynadka NCJ. The zinc regulated antivirulence pathway of Salmonella is a multiprotein immunoglobulin adhesion system. J Biol Chem 2012 287(39):32324-32337. DOI:10.1074/jbc.M112.357210.

Chan PHW, Weissbach S, Okon M, Withers SG and McIntosh LP. Nuclear magnetic resonance spectral assignments of alpha-1,4- galactosyltransferase lgtc from neisseria meningitidis: Substrate binding and multiple conformation-al states. Biochemistry 2012 51(41):8278-8292. DOI:10.1021/bi3010279.

Prehna G, Zhang G, Gong X, Duszyk M, Okon M, McIntosh LP, Weiner JH and Strynadka NCJ. A protein export pathway involving Escherichia coli porins. Structure 2012 20(7):1154-1166. DOI:10.1016/j.str.2012.04.014.

Membership List with Publications |26

L

M

2012 Annual Report

http://www-ncbi-nlm-nih-gov.ezproxy.library.ubc.ca/pubmed/23086564








Hongshen Ma

Assistant Professor Department of Mechanical Engineering

Guo Q, Park S and Ma H. Microfluidic micropipette aspiration for measuring the deformability of single cells. Lab Chip Miniaturisation Chem Biol 2012 12(15):2687-2695. DOI:10.1039/c2lc40205j.

Nisha Malhotra

Instructor (Tenure track) Department of Economics

Fawziah Marra

Professor Faculty of Pharmaceutical Sciences Director Pharmacy and Vaccine Service, BC CDC

Marra F, Patrick DM, Chong M, McKay R, Hoang L and Bowie WR. Population-based study of the increased incidence of skin and soft tissue infections and associated antimicrobial use. Antimicrob Agents

Chemother 2012 56(12):6243-6249. DOI:10.1128/AAC.00649-12.

Marra F, Chong M, McKay R and Patrick D. Antimicrobial use for skin and soft tissue infections in Canada in an era of CA-MRSA. Clin Microbiol Infect 2012 18:66. DOI:10.1111/j.1469-0691.2012.03801.x.

Seto K, Marra F, Raymakers A and Marra CA. The cost effectiveness of human papillomavirus vaccines: A systematic review. Drugs 2012 72(5):715-743. DOI:10.2165/11599470-000000000-00000.

Donald Moerman

Professor Department of Zoology Director C. elegans Knockout Facility

Steve Morgan

Associate Professor School of Population and Public Health

Daw JR, Mintzes B, Law MR, Hanley GE and Morgan SG. Prescription Drug Use in Pregnancy: A Retrospec-tive, Population-Based Study in British Columbia, Cana-da (2001-2006). Clin Ther 2012 34(1):239-249.e2. DOI:10.1016/j.clinthera.2011.11.025.

Daw JR and Morgan SG. Stitching the gaps in the Canadian public drug coverage patchwork? A review of provincial pharmacare policy changes from 2000 to 2010. Health Policy 2012 104(1):19-26. DOI:10.1016/j.healthpol.2011.08.015.

Greyson DL, Cunningham C and Morgan S. Information behaviour of Canadi-an pharmaceutical policy makers. Health Info Libr J 2012 29(1):16-27. DOI:10.1111/j.1471-1842.2011.00969.x.

Law MR, Cheng L, Dhalla IA, Heard D and Morgan SG. The effect of cost on adherence to prescription medications in Canada. CMAJ 2012 184(3):297-302. DOI:10.1503/cmaj.111270.

Morgan S, Cunningham C and Law M. Changing scientific and policy para-digms in the pharmaceutical sector: Reflections from a program of research conducted in partnership with decision makers. J Popul Ther Clin Pharmacol 2012 19(2):e129.

Morgan SG, Cunningham CM and Law MR. Drug development: Innovation or imitation deficit? BMJ 2012 345:e5880. DOI:10.1136/bmj.e5880.

Morgan SG and Daw JR. Canadian pharmacare: Looking back, looking for-ward. Healthc Policy 2012 8(1):14-23.

Michael Murphy

Professor Department of Microbiology & Immunology

Cheung J, Murphy MEP and Heinrichs DE. Discovery of an iron-regulated citrate synthase in staphylococcus aureus. Chem Biol 2012 19(12):1568-1578. DOI:10.1016/j.chembiol.2012.10.003.

Christopher Orvig

Professor Department of Chemistry

Herrmann C, Salas PF, Patrick BO, De Kock C, Smith PJ, Adam MJ and Orvig C. 1,2-Disubstituted ferrocenyl carbohydrate chloroquine conjugates as potential anti-malarial agents. Dalton Trans 2012 41(21):6431-6442. DOI:10.1039/c2dt12050j.

Wingfield Rehmus

Clinical Assistant Professor Department of Pediatrics

Jean-Francois (Mickey) Rostocker

Physician Faculty of Medicine

Laura Sauve

Clinical Assistant Professor Department of Pediatrics Program Director Pediatrics Residency Training Program

Jerry Spiegel

Professor Liu Institute for Global Issues and School of Population and Public Health

Spiegel J, Alegret M, Clair V, Pagliccia N, Martinez B, Bonet M and Yassi A. Intersectoral action for health at a municipal level in Cuba. International Journal of Public

Health 2012, Vol57(1):15-23.


O

R

S


Peter von Dadelszen

Associate Professor Department of Obstetrics & Gynecology

Akkermans J, Ganzevoort W, Payne B, Groen H, Mol BW and von Dadelszen P. Timely prediction of maternal complications in pre-eclampsia analysis of the fullPIERS model. Pregnancy Hypertens 2012 2(3):334-335. DOI:10.1016/j.preghy.2012.04.285.

Bodkin BL, Gordon R, Sawchuck D and Von Dadelszen P. Placental malaria infection as a risk factor for hypertensive disorders of pregnancy in malaria endemic regions: A systematic review and meta-analysis. Pregnancy Hyper-

tens 2012 2(3):189. DOI:10.1016/j.preghy.2012.04.026.

Firoz T, Magee LA, Lalani S, Sawchuck D, Payne B, Vidler M, Gordon R and von Dadelszen P. Oral antihypertensive therapy for severe hypertension in pregnancy. Pregnancy Hypertens 2012 2(3):288. DOI:10.1016/j.preghy.2012.04.199.

Firoz T, Magee LA, Payne BA, Menzies JM and von Dadelszen P. The PIERS experience: research or quality improvement? J Obstet Gynaecol Can 2012 34(4):379-381.

Gordon RM, Payne B, Firoz T, Magee L, Sawchuck D, Tu D, Vidler M and von Dadelszen P. Magnesium sulphate for prevention and treatment of eclampsia in low and middle income countries: Systematic review of tested regimens. Pregnancy Hypertens 2012 2(3):328. DOI:10.1016/j.preghy.2012.04.275.

Hoac T, Zahid A, Mason D, Sanchez J, Asztalos E, Hahnhaussen C, Kirton J, Ross S, von Dadelszen P and Magee LA. Challenges to transitioning from paper-based data collection to electronic data capture. Clin Trials 2012 9(4):530. DOI:10.1177/1740774512453224.

Lalani S, Firoz T, Magee LA, Lowe R, Sawchuck D, Payne B, Gordon R, Vidler M and von Dadelszen P. Pharmacotherapy for pre-eclampsia in low and middle income countries: An analysis of essential medicines lists (EMLS). Pregnancy Hypertens 2012 2(3):193-194. DOI:10.1016/j.preghy.2012.04.033.

Magee LA, Menzies JM, Ross S, Sanchez J, Asztalos E, Kirton J, Hoac T, Zahid A, Hahnhaussen C and von Dadelszen P. Serious unexpected events in an obstetric clinical trial - Definitional challenges. Clin Trials 2012 9(4):516. DOI:10.1177/1740774512453224.

Payne B, Hutcheon JA, Qu Z, Haniff F, Bhutta Z, Biryabarema C, Duan T, Hall DR, Grobman WA, Groen H, Magee LA, Merialdi M, Mirembe F, Nakimuli A, Qureshi R, Sass N, Sikandar R, Steyn W, Widmer M, Zhou V and von Dadelszen P. Minipiers (pre-eclampsia integrated estimate of risk): Develop-ment of a clinical prediction model for use in low and middle income countries (LMIC). Pregnancy Hypertens 2012 2(3):195-196. DOI:10.1016/j.preghy.2012.04.038.

Roberge S, Giguere Y, Villa P, Nicolaides K, Vainio M, Forest J-C, von Dadelzen P, Vaiman D, Tapp S and Bujold E. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: A systematic review and meta-analysis. Am J Perinatol 2012 29(7):551-556. DOI:10.1055/s-0032-1310527.

von Dadelszen P. Measuring the burden of morbidity and mortality related to pre-eclampsia in developing countries-challenges and solutions. Int J Gyne-

col Obstet 2012 119:S256. DOI:10.1016/S0020-7292(12)60412-3.

von Dadelszen P, Ansermino JM, Dumont G, Hofmeyr GJ, Magee LA, Mathai M, Sawchuck D, Teela K, Donnay F and Roberts JM. Improving maternal and perinatal outcomes in the hypertensive disorders of pregnancy: A vision of a community-focused approach. Int J Gynecol Obstet 2012 119 (Suppl.1):S30-S34. DOI:10.1016/j.ijgo.2012.03.012.

Zahid A, Hoac T, Sanchez J, Hahnhaussen EAC, Kirton J, Ross S, von Dadelszen P and Magee LA. Outcomes adjudication - The preparation pro-cess. Clin Trials 2012 9(4):514. DOI:10.1177/1740774512453224.

Kishor Wasan

Professor and Associate Dean Research and Graduate Studies Faculty of Pharmaceutical Sciences Director Neglected Global Diseases Initiative

Ibrahim F, Gershkovich P, Sivak O, Wasan EK, Bartlett K, Wasan KM. Efficacy and toxicity of a tropically stable lipid-based formulation of am-photericin B (iCo-010) in a rat model of invasive candidiasis. Int J Pharm

2012 436(1-2):318-323. DOI:10.1016/j.ijpharm.2012.06.062.

Ibrahim F, Gershkovich P, Sivak O, Wasan EK, Wasan KM. Assessment of novel oral lipid-based formulations of amphotericin B using an in vitro lipolysis model. Eur J Pharm Sci 2012 46(5):323-8. DOI:10.1016/j.ejps.2012.02.008.

Osei-Twum JA and Wasan KM. Neglected populations: Safeguarding the health of street-involved children in Ghana. J Pharm Sci 2012 101(10):3619-3622. DOI:10.1002/jps.23255.

Steve Withers

Professor Department of Chemistry & Biochemistry

Annalee Yassi

Professor School of Population and Public Health and College for Interdisciplinary Studies Canada Research Chair Global Health and Capacity Building

Breilh J, Pagliccia N and Yassi A. Chronic pesticide poisoning from persistent low-dose exposures in Ecuadorean floriculture workers: toward validating a low-cost test battery. Int J Occup Environ Health 2012 18(1):7-21.

Spiegel J, Alegret M, Clair V, Pagliccia N, Martinez B, Bonet M and Yassi A. Intersectoral action for health at a municipal level in Cuba. Int J Public Health 2012 57(1):15-23. DOI: 10.1007/s00038-011-0279-z.

Colby Zaph

Assistant Professor Department of Pathology and Laboratory Medicine

Hadidi S, Antignano F, Hughes MR, Wang SKH, Snyder K, Sammis GM, Kerr WG, McNagny KM and Zaph C. Myeloid cell-specific expression of Ship1 regulates IL-12 production and immunity to helminth infection. Mucosal

Immunol 2012 5(5):535-543. DOI:10.1038/mi.2012.29.

Carvalho LP, Petritus PM, Trochtenberg AL, Zaph C, Hill DA, Artis D and Scott P. Lymph node hypertrophy following Leishmania major infection is dependent on TLR9. J Immunol 2012 188(3):1394-1401. DOI:10.4049/jimmunol.1101018.

Membership List with Publications |28

V W

Y

Z

2012 Annual Report

http://www.wasanlab.com/pubmed/22777650

RESEARCH ASSOCIATES AND POST-DOCTORAL

FELLOWS

Dan Badulescu Research Associate Faculty of Land and Food Systems

Pavel Gershkovich Research Associate Department of Pharmaceutics and Biopharmaceutics

Ibrahim F, Gershkovich P, Sivak O, Wasan EK, Bartlett K, Wasan KM. Efficacy and toxicity of a tropically stable lipid-based formulation of am-photericin B (iCo-010) in a rat model of invasive candidiasis. Int J Pharm

2012 436(1-2):318-323. DOI:10.1016/j.ijpharm.2012.06.062.

Ibrahim F, Gershkovich P, Sivak O, Wasan EK, Wasan KM. Assessment of novel oral lipid-based formulations of amphotericin B using an in vitro lipolysis model. Eur J Pharm Sci 2012 46(5):323-8. DOI:10.1016/j.ejps.2012.02.008.

Rebecca Goulding Musselwhite LW, Maciag K, Lankowski A, Gretes MC, Wellems TE, Tavera G, Goulding RE and Guillen E. First Universities Allied for Essential Medi-cines (UAEM) neglected diseases and innovation symposium. Am J Trop

Med Hyg 2012 86(1):65-74. DOI:10.4269/ajtmh.2012.11-0608.

Walter Karlen Post-Doctoral Fellow/Research Assistant. Faculty of Applied Sciences, Electrical and Computer Engineering in Medicine (CFRI)

Carlos Leon Research Associate Faculty of Pharmaceutical Sciences

Joanna Lubieniecka Research Associate Faculty of Pharmaceutical Sciences

Emily Marden Research Associate Faculty of Law

Marden E and Nelson GR. Intellectual Property and Sharing Regimes in Agricultural Genomics: Finding the Right Balance for Innovation. Drake

Journal of Agricultural Law 2012 17:2.

Nico Marr Research Associate Division of Infectious and Immunological Diseases

Marr N and Turvey SE. Role of human TLR4 in respiratory syncytial virus-induced NF-B activation, viral entry and replication. Innate Immun 2012 18(6):856-865. DOI:10.1177/1753425912444479.

Santiago Ramón-García Post-Doctoral Fellow Department of Microbiology and Immunology

Burian J, Ramón-García S, Howes CG and Thompson CJ. WhiB7, a tran-scriptional activator that coordinates physiology with intrinsic drug resistance in Mycobacterium tuberculosis. Expert Rev Anti-Infect Ther 2012 10(9):1037-1047. DOI:10.1586/eri.12.90.

Burian J, Ramón-García S, Sweet G, Gomez-Velasco A, Av-Gay Y and Thompson CJ. The mycobacterial transcriptional regulator whiB7 gene links redox homeostasis and intrinsic antibiotic resistance. J Biol Chem 2012 287(1):299-310. DOI:10.1074/jbc.M111.302588.

Lim LE, Vilcheze C, Ng C, Jacobs Jr. WR, Ramón-García S, and Thompson CJ. Anthelmintic Avermectins Kill Mycobacterium tuberculosis, Including Multidrug-Resistant Clinical Strains: Antimicrob Agents Chemother, published ahead of print Nov 2012. DOI: 10.1128/AAC.01696-12.

Ramón-García S, Mick V, Dainese E, Martin C, Thompson CJ, De Rossi E, Manganelli R and Ainsa JA. Functional and genetic characterization of the tap efflux pump in Mycobacterium bovis BCG. Antimicrob Agents Chemother 2012 56(4):2074-2083. DOI:10.1128/AAC.05946-11.

Benjamin Warren Post-Doctoral Fellow Liu Institute for Global Issues

GRADUATE STUDENTS

Raquel Baldwinson

Laura Bandy

Jennifer Choi

Richmond Ellison

Alexandre Liautaud

Lillian Lourenco

Lyndsay O’Hara

Jo-Ann Osei-Twum

Osei-Twum JA and Wasan KM. Neglected populations: Safeguarding the health of street-involved children in Ghana. J Pharm Sci 2012 101(10):3619-3622. DOI:10.1002/jps.23255.

Rene Pedroza

Olga Pena

Afacan NJ, Yeung ATY, Pena OM and Hancock REW. Therapeutic potential of host defense peptides in antibiotic-resistant infections. Curr Pharm Design

2012 18(6):807-819. DOI:10.2174/138161212799277617.

Maryvonne Rosamont-Ursulet

Kathleen Wee



http://www.wasanlab.com/pubmed/22777650

Photo Credits|30

Credits for photos not in the public domain:

Page 5: Toshihiro Horii, Department of Molecular Protozoology, Research Institute for Microbial Diseases, University of Osaka, Osaka, Japan

Page 9: Image by Ute Frevert; false color by Margaret Shear

Page 11: Pete Lewis / Department for International Development

Page 16: Charles Larson, used by permission.

2012 Annual Report

For more information contact the Coordinator: Jocelyn Conway Telephone: (604) 827-1571 Email: [email protected] Website: www.ngdi.ubc.ca

The Neglected Global Diseases Initiative at the University of British Columbia

#5504—2405 Wesbrook Mall Vancouver, BC, Canada V6T 1Z3

NGDI-UBC Annual Report 2012R

Documents

faculty of science director

ngdi advisory board

faculty of medicine

ngdiubc advisory board

ngdi office

faculty of law

managing director

drug research development